Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is worrying, and the application of heparin in COVID‐19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated.

[1]  G. Fonarow,et al.  COVID-19 Pandemic: Cardiovascular Complications and Future Implications , 2020, American Journal of Cardiovascular Drugs.

[2]  L. Paz-Ares,et al.  SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death , 2020, European Journal of Cancer.

[3]  F. Potus,et al.  COVID-19 and the pulmonary vasculature , 2020, Pulmonary circulation.

[4]  D. Kell,et al.  The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria , 2020, Frontiers in Immunology.

[5]  M. Salifu,et al.  Management of ST-Elevation Myocardial Infarction in the COVID-19 Era: The Role of Thrombosis and Anticoagulation Strategy , 2020, American journal of medical case reports.

[6]  Jianjun Gao,et al.  Discovering drugs to treat coronavirus disease 2019 (COVID-19). , 2020, Drug discoveries & therapeutics.

[7]  Lei Liu,et al.  Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19) , 2020 .

[8]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[9]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[10]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[11]  T. van der Poll,et al.  Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation , 2019, Journal of thrombosis and haemostasis : JTH.

[12]  N. Gupta,et al.  The stimulation of thrombosis by hypoxia. , 2019, Thrombosis research.

[13]  M. Weigand,et al.  Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study , 2019, Annals of Intensive Care.

[14]  A. Matsuda,et al.  The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J‐SSCG 2016) , 2018, Acute medicine & surgery.

[15]  J. Jenny,et al.  European guidelines on perioperative venous thromboembolism prophylaxis: Day surgery and fast-track surgery. , 2017, European journal of anaesthesiology.

[16]  J. Thachil,et al.  New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey , 2017, BMJ Open.

[17]  E. Hawk,et al.  Platelet “first responders” in wound response, cancer, and metastasis , 2017, Cancer and Metastasis Reviews.

[18]  P. Libby,et al.  More than an anticoagulant: Do heparins have direct anti-inflammatory effects? , 2016, Thrombosis and Haemostasis.

[19]  T. van der Poll,et al.  Coagulation and sepsis. , 2017, Thrombosis research.

[20]  Y. Umemura,et al.  Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta‐analysis of randomized controlled trials , 2016, Journal of thrombosis and haemostasis : JTH.

[21]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[22]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[23]  J. Thachil,et al.  Anticoagulant therapy for sepsis‐associated disseminated intravascular coagulation: the view from Japan , 2014, Journal of thrombosis and haemostasis : JTH.

[24]  Y. Jaladat,et al.  Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study , 2013, Experimental and therapeutic medicine.

[25]  N. Zakai,et al.  Racial differences in venous thromboembolism , 2011, Journal of thrombosis and haemostasis : JTH.

[26]  I. Maruyama,et al.  THROMBOMODULIN ALFA IN THE TREATMENT OF INFECTIOUS PATIENTS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION: SUBANALYSIS FROM THE PHASE 3 TRIAL , 2011, Shock.

[27]  J. Degen,et al.  Reduced thrombin generation increases host susceptibility to group A streptococcal infection. , 2009, Blood.

[28]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[29]  P. Stein,et al.  Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. , 2004, The American journal of medicine.